title: [Efficacy of intra-arterial chemotherapy with reservoir for patients with unresectable hepatocellular carcinoma].
abstract: Long-term results of intra-arterial chemotherapy using a reservoir (IA) for patients with unresectable hepatocellular carcinoma (HCC) were investigated. Ninety-nine patients with unresectable HCC who were treated in our department during the past 7 years were enrolled in this study. Thirty-four out of the 99 patients were treated by IA with a conventional reservoir (SR group), and 21 by IA with a double-lumen reservoir (DR group) by which IA with occlusion of hepatic arterial flow would be possible. The other 44 patients were treated by transcatheter arterial embolization (TAE group). Cumulative 1-and 2-year survival rates were 54.2 and 21.7% in DR group, respectively, and 50.8 and 35.2% in TAE group, respectively. The results of these two groups were statistically equivalent, and were more favorable than those of the SR group. Cumulative patency rate of reservoirs was maintained at 93.7% after one year and at 61.8% after two years. No difference was recognized in this rate according to the type of reservoir. We concluded that IA with a double-lumen reservoir should be taken into consideration as one of the strategies for treatment of unresectable HCC. However, maintenance of catheter-patency would be necessary for satisfactory outcome.
authors.affiliation: First Department of Surgery, Hokkaido University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yasuhara
authors.forename: Y
authors.initials: Y
authors.lastname: Une
authors.forename: T
authors.initials: T
authors.lastname: Shimamura
authors.forename: K
authors.initials: K
authors.lastname: Misawa
authors.forename: Y
authors.initials: Y
authors.lastname: Masuko
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004621:Embolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin